06
February
2023
|
10:59 AM
Europe/Amsterdam
Not intended for U.S. and UK Media
Exciting News!
Positive Results for Aflibercept 8 mg
We are thrilled to announce that we have filed for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on positive results of clinical trials, PULSAR and PHOTON.